News & Events about Ironwood Pharmaceuticals Inc.
Ironwood Pharmaceuticals, Inc. (Ironwood) (Nasdaq: IRWD), a GI-focused healthcare company, and VectivBio Holding AG (VectivBio) (Nasdaq: VECT), a global clinical-stage biopharmaceutical company pioneering novel, transformational treatments for severe rare gastrointestinal conditions, today...
Ironwood Pharmaceuticals, Inc. (Ironwood) (Nasdaq: IRWD), a GI-focused healthcare company, and VectivBio Holding AG (VectivBio) (Nasdaq: VECT), a global clinical-stage biopharmaceutical company pioneering novel, transformational treatments for severe rare gastrointestinal conditions, today...
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the supplemental New Drug Application (sNDA) for LINZESS (linaclotide) for the treatment of children and adolescents ages...
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD Get Rating) CEO Thomas A. Mccourt sold 110,962 shares of the companys stock in a transaction dated Thursday, January 5th. The stock was sold at an average price of $12.07, for a total transaction of $1,339,311.34. Following the completion of the ...